98%
921
2 minutes
20
The persistent threat of emerging and re-emerging viral infections underscores the urgent need for the continuous development of next-generation antiviral agents. The deoxygenative functionalization of oxygen-containing compounds offers a powerful route to address this challenge. Herein, we report a radical-mediated deoxyphosphoamination of ketones to synthesize a new class of antiviral compounds, including -(2-(diphenylphosphoryl)-1-inden-3-yl)-,-diphenylphosphinic amide (IDPA) and its homologues. This transformation proceeds under simple, mild, and easily operable reaction conditions, exhibiting a broad substrate scope and excellent functional group tolerance. Mechanistic investigations, including control and radical inhibition experiments, high-resolution mass spectrometry detection of key intermediates, and density functional theory calculations, reveal a concerted pathway involving nitrogen, oxygen, and phosphorus radicals that facilitate N-O bond cleavage and the formation of C═C, C-P, and N-P bonds. Biological evaluations demonstrate that these scaffolds possess potent broad-spectrum antiviral activity with low cytotoxicity. Proteomic analysis, molecular docking, and Western blotting further elucidate the mechanism by which IDPA inhibits porcine reproductive and respiratory syndrome virus (PRRSV) replication through its interactions with receptor protein CD163 and host protein HSP70. These findings establish a versatile strategy for developing radical-based antiviral agents and provide promising candidates for therapeutic intervention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jacs.5c10745 | DOI Listing |
Front Cell Infect Microbiol
September 2025
Universidad Autónoma de Nuevo León, Servicio y Departamento de Inmunología, Facultad de Medicina, Monterrey, NL, Mexico.
Natural killer (NK) cells are innate lymphocytes with cytotoxic activity against tumors and viruses. The pandemic of the coronavirus disease 2019 (COVID-19) has increased the investigation of their role in disease severity. However, their functional status and modulators remain controversial.
View Article and Find Full Text PDFBackgroundRAY1216 is an alpha-ketoamide-based peptide inhibitor of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) major protease (M). This study evaluated the absorption, distribution, metabolism and excretion of [C]-labelled RAY1216 by oral administration.Research design and methodsThis phase Ι study was designed to assess the pharmacokinetics, mass balance and metabolic pathways in 6 healthy Chinese adult men after a single fasting oral administration of 240 mL (containing 400 mg/100 μCi) [C] RAY1216.
View Article and Find Full Text PDFImmunol Cell Biol
September 2025
Department of Biotechnology, Indian Institute of Technology Hyderabad (IITH), Sangareddy, Telangana, India.
The immune system uses a variety of DNA sensors, including endo-lysosomal Toll-like receptors 9 (TLR9) and cytosolic DNA sensor cyclic GMP-AMP (cGAMP) synthase (cGAS). These sensors activate immune responses by inducing the production of a variety of cytokines, including type I interferons (IFN). Activation of cGAS requires DNA-cGAS interaction.
View Article and Find Full Text PDFTurk J Pediatr
September 2025
Division of Pediatric Infectious Diseases, Faculty of Medicine, İstanbul University, İstanbul, Türkiye.
Aim: This study aimed to describe barriers and facilitators of the adherence of children with human immunodeficiency virus (HIV) to antiretroviral therapy (ART) from the perspectives of their caregivers.
Methods: In-depth interviews were held with the caregivers of 15 children. The collected data were analyzed using thematic analysis procedures.
Neurology
October 2025
Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies - EpiCARE, Rome, Italy.
Objectives: Neuronal ceroid lipofuscinosis type 3 (CLN3) is a rare lysosomal storage disorder characterized by progressive neurodegeneration. No disease-modifying treatments are currently available. Miglustat, a substrate reduction therapy, has shown preclinical efficacy in CLN3 models (conference abstract).
View Article and Find Full Text PDF